country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Art. -Nr.: HY-179585

Copy Link Print Information

DD-CIP2

DD-CIP2 is a DNA damage and apoptosis inducer. DD-CIP2 demonstrates effective anti-proliferative activity against multiple cancer cell. DD-CIP2 modulates the DNA damage response pathway, triggering robust DNA damage, cell cycle arrest, and apoptosis in vitro. DD-CIP2 demonstrates significant anti-tumor efficacy in vivo at well-tolerated doses, without substantial toxicity. DD-CIP2 exhibits superior cytotoxic potency against a broad panel of blood-and solid-tumor-derived cancer cell lines independent of their BRCA1/2 status. DD-CIP2 can be used for small-cell lung cancer (SCLC) and non small-cell lung cancer (NSCLC) research.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Formel: C₅₂H₅₄ClFN₁₀O₅S
Molecular Weight:985.57

Speicherung:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (278 KB)

DD-CIP2 Chemical Structure

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- In Vitro
- Parmacokinetics
- In Vivo
Chemical Information
Reinheit & Dokumentation
Verweise
Calculators
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

In Vitro

DD-CIP2 can target a broad spectrum of cancers with IC₅₀ = 12 nM in Jurkat cell, IC₅₀ = 12 nM in KARPASS422 cell, IC₅₀ = 11 nM in Raji cell, IC₅₀ = 2 nM in Daudi cell, IC₅₀ = 9.3 nM in TYK-nu cell, and IC₅₀ < 10 nM in MDA-MB-436, IC₅₀ = 0.8 nM in SU-DHL-5 cells, IC₅₀ = 4.6 nM in MOLT-4^[1].
^[1]
DD-CIP2 displays only a modest increase of PARP1 occupancy with EC₅₀ = 42 nM^[1].
DD-CIP2 (0.1-100 nM, 24 h) induces PARP1-BRD4 interaction in HEK293T cells and reduces DNA damage in both GLC16 and NCI-H82 cell lines^[1].
DD-CIP2 (0.1-0.8 nM, 72 h) demonstrates the dependency on the PARP-170 BRD4 association in SU-DHL-5 cell^[1].
DD-CIP2 (10 μM, 24 h) stalles cell cycle progression in GLC16 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:

HEK293T cells
Concentration:

0.1, 1, 10 and 100 nM
Incubation Time:

24 h
Result:

Elevated levels of γH2AX and cleaved PARP1 in both GLC16 and NCI-H82 cell.
Increased the phosphorylation of RPA32 at Ser4/Ser8 in both GLC16 and NCI-H82 cell.

Cell Cycle Analysis^[1]

Cell Line:

GLC16 cells
Concentration:

10 μM
Incubation Time:

24 h
Result:

Provoked a dose-dependent accumulation of 199 cells in the G2/M phase.

Parmacokinetics

Species	Dose	Route	T_1/2	T_max	C_max
Mice^[1]	10 mg/kg	i.p.	2.75 h	1 h	3.90 μM
Mice^[1]	3 mg/kg	i.v.	3 h	0.08 h	7.66 μM

In Vivo

DD-CIP2 (20 mg/kg, i.p., once for 5 days or 28 days) achieves potent and well-tolerated anti- tumor activity with no apparent systemic toxicity in a human SCLC xenograft mice model^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

GLC16 cells (2 × 10⁶, s.c.) induced NU-Foxn1nu mice (8 weeks)^[1]
Dosage:

20 mg/kg
Administration:

i.p., once for 5 days
Result:

Induced a dose-dependent increase in γH2AX and cleaved PARP1, confirming target engagement.
Was well tolerated at doses up to 20 mg/kg, with no significant body weight loss.

Animal Model:

GLC16 cells (2 × 10⁶, s.c.) induced NU-Foxn1nu mice (8 weeks)^[1]
Dosage:

20 mg/kg
Administration:

i.p., once for 28 days
Result:

Showed strong tumor regression as early as day 3, with 210 durable suppression maintained throughout the experiment period.
Detected no obvious toxicity as indicated by steady body weight.

Chemical Information

Molecular Weight 985.57
Formel C₅₂H₅₄ClFN₁₀O₅S
SMILES

FC1=CC=C(CC2=NNC(C3=CC=CC=C32)=O)C=C1C(N(CC4)CCN4C(C(CC5)CCC65CCN(C(CNC(C[C@H]7C8=NN=C(C)N8C(SC(C)=C9C)=C9C(C%10=CC=C(Cl)C=C%10)=N7)=O)=O)CC6)=O)=O
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

Please store the product under the recommended conditions in the Certificate of Analysis.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (278 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Qiu T, et al. Design and Development of DNA Damage Chemical Inducers of Proximity (DD-CIP) for Targeted Cancer Therapy. bioRxiv [Preprint]. 2025 Nov 4:2025.11.03.686423. [Content Brief]

Calculators

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

100 mg

Angebot einholen Auf Lager